Haemonetics Q1 FY27: Revenue +5.6%, Adjusted EPS $1.14, Raises Full-Year Guidance
HAE sits 76% above its 52-week low of $47.315.
Summary
Haemonetics reported Q1 FY27 revenue of $339.4 million, up 5.6%, with adjusted EPS of $1.14. The company raised its full-year revenue growth guidance to 5-8% and maintained margin and cash flow targets.
Key Events · Earnings and Guidance · HAE
-
Q1 Revenue and EPS Beat
Revenue of $339.4 million grew 5.6% reported and 5.9% organic. Adjusted EPS of $1.14 exceeded expectations, driven by strength in Plasma and Blood Management Technologies.
-
Full-Year Guidance Raised
Management lifted fiscal 2027 reported revenue growth guidance to 5-8% (from 4-7%) and organic growth to 4-7% (from 3-6%), while maintaining adjusted operating margin expansion of 50-100 bps and ~80% free cash flow conversion.
-
Strong Cash Flow Generation
Operating cash flow was $52.3 million, up $34.9 million year-over-year, and free cash flow reached $39.1 million, up from $2.5 million, driven by favorable working capital and lower equipment transfers.
-
Segment Performance
Apheresis revenue grew 5.3% reported (6.0% organic) led by Plasma up 7.2%. MedSurg grew 6.0% reported (5.9% organic) with Blood Management Technologies up 8.6% and Interventional Technologies returning to growth at 2.5%.
Analysis · HAE · Industrial Applications And Services
Haemonetics delivered a solid start to fiscal 2027 with 5.9% organic revenue growth and raised its full-year outlook. The guidance raise signals management confidence in sustained momentum across both Apheresis and MedSurg segments. Adjusted EPS of $1.14 beat expectations, and free cash flow improved sharply to $39 million from $2.5 million a year ago, strengthening the balance sheet. The stock is likely to react positively to the combination of a beat and a raise.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HAE was trading at $83.50 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $47.32 to $88.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.